tiprankstipranks
Trending News
More News >
Zevra Therapeutics: Strong Financial Performance and Strategic Initiatives Drive Buy Rating
PremiumRatingsZevra Therapeutics: Strong Financial Performance and Strategic Initiatives Drive Buy Rating
2M ago
Zevra Therapeutics: Strong Sales and Strategic Initiatives Drive Buy Rating
Premium
Ratings
Zevra Therapeutics: Strong Sales and Strategic Initiatives Drive Buy Rating
2M ago
Promising Outlook for Zevra Therapeutics: Buy Rating Driven by Strong Miplyffa Launch and Robust Financial Performance
Premium
Ratings
Promising Outlook for Zevra Therapeutics: Buy Rating Driven by Strong Miplyffa Launch and Robust Financial Performance
2M ago
Zevra Therapeutics urges stockholders to vote for director nominees
PremiumThe FlyZevra Therapeutics urges stockholders to vote for director nominees
3M ago
Zevra Therapeutics announces publication on arimoclomol
Premium
The Fly
Zevra Therapeutics announces publication on arimoclomol
3M ago
Zevra Therapeutics closes sale of Rare Disease PRV for $150M
Premium
The Fly
Zevra Therapeutics closes sale of Rare Disease PRV for $150M
3M ago
Zevra Therapeutics price target raised to $25 from $23 at Canaccord
PremiumThe FlyZevra Therapeutics price target raised to $25 from $23 at Canaccord
4M ago
Zevra Therapeutics: Strong Buy Rating Backed by Impressive Sales and Robust Financial Position
Premium
Ratings
Zevra Therapeutics: Strong Buy Rating Backed by Impressive Sales and Robust Financial Position
4M ago
Zevra Therapeutics’ Earnings Call Highlights Success and Growth
Premium
Company Announcements
Zevra Therapeutics’ Earnings Call Highlights Success and Growth
4M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100